XML 56 R46.htm IDEA: XBRL DOCUMENT
v3.19.2

Revenue Disaggregated Revenue by Product Line (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 312,282 | $ 360,460 | $ 643,214 | $ 732,493
Infusion Consumables [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 117,669 | 123,782 | 238,249 | 243,693
IV Solutions [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 102,635 | 135,325 | 215,817 | 279,765
Infusion Systems [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 81,309 | 88,376 | 165,591 | 181,815
Critical Care [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 10,669 | $ 12,977 | $ 23,557 | $ 27,220

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=icui_InfusionConsumablesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=icui_IVSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=icui_InfusionSystemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=icui_CriticalCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |